Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation. The Companyâs mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates. Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics. Source
No articles found.
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
NRC Health is one of the nationâs largest healthcare performance improvement fir...
NRC Health is one of the nationâs largest hea...
NantHealth is a next-generation, evidence-based, personalized healthcare company e...
NantHealth is a next-generation, evidence-based...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.